No Data
No Data
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $7
Express News | Chemomab Therapeutics- Reinforces and Expands Positive Results From 15-Week Double-Blind Phase 2 Spring Trial
Express News | Chemomab Therapeutics Ltd - Treatment for up to 48 Weeks Was Well-Tolerated
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
12 Health Care Stocks Moving In Tuesday's After-Market Session
Chemomab Therapeutics Updates ADS Offering Under Sales Agreement